Clinical Trials
20
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease
- Conditions
- Acute Graft Versus Host Disease
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- Henogen
- Target Recruit Count
- 12
- Registration Number
- NCT00640497
- Locations
- 🇳🇱
Department of Hematology Radboud University Nijmegen (RUN), Nijmegen, Netherlands
🇳🇱Department of Hematology Erasmus MC/Daniel den Hoed Cancer CenterGroene Hilledijk, Rotterdam, Netherlands
🇳🇱L.F. , Department of HematologyUMC Utrecht, Utrecht, Netherlands
Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule
- Conditions
- Hepatitis B
- First Posted Date
- 2007-05-30
- Last Posted Date
- 2008-08-25
- Lead Sponsor
- Henogen
- Target Recruit Count
- 450
- Registration Number
- NCT00480116
- Locations
- 🇨🇿
Vaccination and Travel Medicine Centre Poliklinika II, Hradec Kralove, Czech Republic
Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™
- Conditions
- Hepatitis B
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Henogen
- Target Recruit Count
- 102
- Registration Number
- NCT00445185
- Locations
- 🇧🇪
O.L.Vrouwziekenhuis Aalst, Aalst, Belgium
🇧🇪RHMS La Madeleine ATH, Ath, Belgium
🇧🇪RHMS Clinique Louis Caty Baudour, Baudour, Belgium
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
- Conditions
- Epstein Barr Virus (EBV) Infection
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2007-02-02
- Lead Sponsor
- Henogen
- Target Recruit Count
- 200
- Registration Number
- NCT00430534
- Locations
- 🇧🇪
GSK Clinical Trials Call Center, Brussels, Belgium
A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.
- Conditions
- Hepatitis B
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2008-08-28
- Lead Sponsor
- Henogen
- Target Recruit Count
- 185
- Registration Number
- NCT00291980
- Locations
- 🇧🇪
O.L.Vrouwziekenhuis Aalst, Aalst, Belgium
🇧🇪RHMS La Madeleine ATH, ATH, Belgium
🇧🇪RHMS Clinique Louis Caty Baudour, Baudour, Belgium
- Prev
- 1
- 2
- Next